ASCO 2014: Highlights in Multiple Myeloma

Please Log In or Register to continue.

Release Date: June 17, 2014
Expiration Date: June 17, 2015

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Advancements in multiple myeloma have changed the disease course in the past decade, where survival has nearly tripled, and while still considered incurable, this malignancy is transitioning to one more reminiscent of a chronic disease when appropriately managed. Nevertheless, with only 20,000 cases diagnosed annually, multiple myeloma is a small population cancer with which the majority of community oncology practitioners will have relatively little experience managing in their practice. With the rapid pace of clinical developments in the treatment and management of multiple myeloma, it is essential that the multidisciplinary community oncology health team members who care for patients with this malignancy remain current with practice changing studies which are frequently first reported at large annual meetings.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in the treatment of multiple myeloma patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Recognize recent clinical findings regarding the monitoring and treatment of multiple myeloma including relevant efficacy, safety and/or trial limitations
  • Relate how these clinical trial findings may impact current or future practice

Agenda

ASCO 2014: Highlights in Multiple Myeloma – Noopur Raje, MD (Moderator)

Where We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma – P. Leif Bergsagel, MD

Favoring Novel-based Regimens Given Continuously versus Melphalan and Seeking Predictive Markers for the Efficacy of IMID-based Therapy: Ikaros and Cereblon – A. Keith Stewart, MB ChB

Advancements in Immunotherapeutics for Multiple Myeloma – Sagar Lonial, MD

Advances in the Management of Newly Diagnosed Multiple Myeloma – Andrzej Jakubowiak, MD, PhD

Practice Changing Trials in Relapsed Refractory Disease Management and Risk-Modeling in Smoldering Myeloma – Jesus San Miguel, MD, PhD

Instructions for Participation and Credit
This activity is eligible for credit through June 17, 2015. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Noopur Raje, MD
Director, Multiple Myeloma Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University, India. She has trained in internal medicine at Massachusetts General Hospital (MGH) and has completed a fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute, Boston. Dr. Raje has a joint faculty appointment at MGH and Dana-Farber Cancer Institute. She is an associate professor of medicine at Harvard Medical School and is the director of the Multiple Myeloma Program, Medical Oncology, at MGH. As a hematologist/oncologist at MGH, Dr. Raje’s primary focus is in multiple myeloma and related research. Her laboratory focuses on bone biology and the development of novel therapeutics for multiple myeloma, as well as identifying and validating novel targets and translating them into clinical trials.

Dr. Raje is a member of the American Medical Association, America Society of Hematology, American Society of Clinical Oncology, and American Association of Cancer Research, she is also an ad hoc reviewer for several journals including Blood, Clinical Cancer Research, Leukemia, and the American Journal of Hematology. Dr. Raje is the recipient of several awards and has published extensively in the field of multiple myeloma research. Her hope is to continue pursuing laboratory and clinical research in the area of multiple myeloma with the goal of translating her efforts to the improvement of patients’ lives.

P. Leif Bergsagel, MD
Professor of Medicine
Mayo Clinic
Scottsdale, Arizona

Dr. P. Leif Bergsagel received his medical degree from the University of Toronto. He completed his internal medicine internship and residency at Sunnybrook Medical Centre, as well as an internal medicine residency at Stanford University Medical Center, and a medical oncology fellowship at the National Cancer Institute, National Institutes of Health. Dr. Bergsagel is professor of medicine, College of Medicine, at the Mayo Clinic where he is also a consultant in the Division of Hematology/Oncology, Department of Internal Medicine.

Dr. Bergsagel is American Board of Internal Medicine (ABIM) certified in internal medicine and medical oncology, and is certified by the Medical Council of Canada, LMCC. He has held professional memberships in the American Association for Cancer Research, American Federation for Medical Research, American Society of Clinical Oncology, American Society of Hematology, and the Association of American Physicians. Dr. Bergsagel was a grant reviewer for the International Myeloma Foundation, Leukemia and Lymphoma Society, Leukemia Research Foundation, National Institutes of Health, National Cancer Institute, and scientific advisor for Multiple Myeloma Research Foundation. He has held editorial positions at Clinical Lymphoma and Humana Press, Inc., Recent Advances in the Biology of Multiple Myeloma, as well as numerous other journal responsibilities. In addition, he has written many peer-reviewed articles, book chapters, and abstracts. Dr. Bergsagel’s primary research interest is in molecular pathogenesis of multiple myeloma.

A. Keith Stewart, MB ChB, MRCP, FRCPC, MBA
Dean for Research
Vasek and Anna Maria Polak Professor of Cancer Research
Consultant, Division of Hematology/Oncology
Mayo Clinic
Phoenix, Arizona

Dr. Keith Stewart received his medical degree at Aberdeen University Medical School and trained in internal medicine and hematology at Glasgow Royal Infirmary, Queens University in Kingston, University of Toronto, and New England Medical Center in Boston. He completed a master’s degree in business administration at the Ivey Business School, University of Western Ontario, and subsequently held administrative positions as director of research at Toronto General Hospital and as director of the McLaughlin Centre for Molecular Medicine at the University of Toronto. Dr. Stewart joined Mayo Clinic in Arizona as a consultant in the Division of Hematology/Oncology and is the Dean for Research at Mayo Clinic in Arizona. He holds the Vasek and Anna Maria Polak Professorship in Cancer Research.

Dr. Stewart serves on the scientific advisory board of the Multiple Myeloma Research Foundation, and is a founding member of the Multiple Myeloma Research Consortium. He serves on the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society. He has also served as associate editor of Blood, and was chair of the NIH Developmental Therapeutics Study Section. Dr. Stewart’s lab-based research has focused on multiple myeloma genomics and developmental therapeutics. He has led numerous clinical trials from “first in man,” through large international phase III studies. Funding for his research is from the National Cancer Institute, the Leukemia and Lymphoma Society (LLS) and the Multiple Myeloma Research Foundation (MMRF).

Sagar Lonial, MD
Professor
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is a professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University where he is also the vice chair of clinical affairs, as well as director of the Translational Research for the B-Cell Malignancy Program. He is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. In addition, he serves on the editorial board of the Journal of Clinical Oncology, Leukemia, and is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia, and also serves as an invited and ad hoc reviewer for several publications including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others. Dr. Lonial has authored/coauthored over 200 publications and recently was awarded the Celgene ‘Young Investigator’ Award, the MMRF ‘Top 15 Innovator’ Award, and the MMRC ‘Center of the Year’ award.

Dr. Lonial’s research interest is on combination therapy in B-cell malignancies focusing on myeloma. He is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and myeloma. His clinical interests include evaluating the combination of new molecular targeted agents for B-cell tumors as well as target discovery and validation.

Andrzej Jakubowiak, MD, PhD
Professor of Medicine
Director, Myeloma Program
University of Chicago Medical Center
Chicago, Illinois

Dr. Andrzej Jakubowiak received both his medical degree and his PhD from the Medical Academy in Poznan, Poland, where he also completed an internship and residency. He then completed a postdoctoral fellowship in obstetrics and gynecology, as well as residencies in pathology and internal medicine at The University of Texas Medical School, Houston.  Dr. Jakubowiak is currently professor of medicine, and director of the myeloma program at the University of Chicago Medical Center.

An internationally known expert on multiple myeloma, a cancer of the plasma cells in bone marrow, Dr. Jakubowiak works closely with the Multiple Myeloma Research Consortium (MMRC) to bring the latest treatments to the patient’s bedside as quickly as possible. His primary research focus is in the development of new drugs for the treatment of multiple myeloma. Dr. Jakubowiak has presented these research findings at medical meetings around the world and has published numerous peer-reviewed articles and book chapters. He serves as an ad hoc reviewer for several scientific journals, including the Journal of Clinical Oncology, Blood and Leukemia and Lymphoma. Dr. Jakubowiak is currently the lead investigator on a number of multi-site clinical trials for patients who are newly diagnosed, have relapsed, or have refractory (resistant to treatment) disease.

Jesus San Miguel, MD, PhD
Professor of Hematology
University of Salamanca
Director of Clinical and Translational Medicine
University of Navarra
Navarra, Spain

Dr. Jesus San Miguel is professor of medicine (hematology), director of clinical and translational medicine at the University of Navarra. He had served as director of the Hematology Department of the University Hospital of Salamanca for over 22 years.

Dr. San Miguel is president elect of the International Myeloma Society, a member of the Academy of Pharmacy of Castilla Leon, and honorary member to the Royal Academy of Medicine of Salamanca, as well as a member of the advisory board of the International Myeloma Foundation, the Multiple Myeloma Research Foundation, Carreras Foundation, and a board member of the Spanish Hematology and Genome Foundations. He is associate editor of Blood and also was associate editor of Haematologica; in addition he is a member of the editorial board of several scientific journals. Dr. San Miguel has served as director of the Biomedical Research Institute of Salamanca, Spain, vice director of the Cancer Research Center, Salamanca, Spain, and as chairman of the Spanish Myeloma Group (GEM), as well as the European Association as Board Councillor, chairman of the Scientific Committee for the 9th congress, and president for the 15th EHA Congress. In addition he organized the IXth International Myeloma Workshop held in Salamanca.

Dr. San Miguel has published over 600 original papers in international journals. His areas of interest include multiple myeloma, the biology of leukemic cells and their prognostic implications, and minimal residual disease.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE

CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-14-015-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

 

MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: Program Number: 14-015-350

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Noopur Raje has received honoraria as a consultant from Amgen Inc., Celgene Corporation, Millennium: The Takeda Oncology Company, and Onyx.

Dr. P. Leif Bergsagel has received honoraria as a consultant from Novartis AG and Onyx.

Dr. Keith Stewart has received honoraria as a consultant from Array BioPharma, Bristol-Myers Squibb, Celgene Corporation, and Sanofi.

Dr. Sagar Lonial has received honoraria as a consultant from Bristol-Myers Squibb, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis AG, Onyx, and Sanofi.

Dr. Andrzej Jakubowiak has received honoraria as a consultant as well as grant support related to research activities from Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Inc., Millennium: The Takeda Oncology Company, Novartis AG, and Onyx. He has received honoraria related to formal advisory activities from Millennium.

Dr. Jesus San Miguel has received honoraria related to formal advisory activities from Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Millennium: The Takeda Oncology Company, Novartis AG, and Onyx.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Drs. Raje, Lonial, and San Miguel have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Drs. Bergsagel, Stewart, and Jakubowiak have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Drs. Raje, Bergsagel, Lonial, and San Miguel have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Drs. Stewart and Jakubowiak have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managingmyeloma.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Millennium: The Takeda Oncology Company and Celgene Corporation

©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.